nam/aidsmap, Published: 26 January 2016 Two statisticians involved in the PROUD and iPrEx trials of pre-exposure prophylaxis (PrEP) warn that future trials to test new PrEP drugs and formulations may be extremely difficult to design. David Dunn of the UK Medical Research Council and David Glidden of the University of California, San Francisco say that statisticians will need to choose and analyse...
ScienceDaily, December 23, 2015 In one of the most tightly controlled trials ever conducted of drugs used to treat sexually transmitted infections, researchers at the University of Alabama at Birmingham have confirmed that azithromycin remains effective in the treatment of urogenital chlamydia. In a study published Dec. 24 in the New England Journal of Medicine, the research team compared two of...
NAM , 02 December 2015 The results from the Ipergay study of intermittent pre-exposure prophylaxis (PrEP) were published in the New England Journal of Medicine (NEJM) on 1 December, World AIDS Day. The journal-published results are little changed from those presented at the CROI conference last February by principal investigator Jean-Michel Molina, but the researchers make a number of additional...
nam/aidsmap, 28 October 2015 While epidemiologists and public health experts are excited by the potential of new hepatitis C drugs to limit onward transmission of the virus among people who inject drugs, the strategies ignore profound barriers to drug users engaging with healthcare and their broader needs. For ‘treatment as prevention’ to be ethical and acceptable to people who inject drugs...
A forum to discuss the role of Pre-Exposure Prophylaxis (PrEP) and how it could work in the prevention of HIV in South Australia Thursday 26 November 6:30 | PM 57 Hyde Street, Adelaide | Free event | Catering provided SA Mobilisation + Empowerment for Sexual Health (SAMESH) and the Australasian Society for HIV, Viral Hepatitis and Sexual Health Medicine (ASHM) are bringing leading HIV clinicians...
nam, 27 July 2015
An open-label demonstration project of Truvada pre-exposure prophylaxis (PrEP) in the United States has found generally high retention and adherence rates, with the highest adherence among those at the highest risk of HIV.
Read more here